Cargando…

Targeting MYC for triple-negative breast cancer treatment

Detalles Bibliográficos
Autores principales:	Klauber-DeMore, Nancy, Schulte, Bradley A., Wang, Gavin Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049315/ https://www.ncbi.nlm.nih.gov/pubmed/30035158 http://dx.doi.org/10.18632/oncoscience.414

Ejemplares similares

The Value of a Second Opinion for Breast Cancer Patients Referred to a National Cancer Institute (NCI)-Designated Cancer Center with a Multidisciplinary Breast Tumor Board
por: Garcia, Denise, et al.
Publicado: (2018)

Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
por: Yeh, Elizabeth S., et al.
Publicado: (2017)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus
por: Siamakpour-Reihani, Sharareh, et al.
Publicado: (2011)

Optimizing ultrasound molecular imaging of secreted frizzled related protein 2 expression in angiosarcoma
por: Tsuruta, James K., et al.
Publicado: (2017)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

MON-532 Characterization of the Angiogenic Factor SFRP2 in Papillary Thyroid Carcinoma
por: Wofford, Wyatt O, et al.
Publicado: (2020)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

Ultrasound Molecular Imaging of Secreted Frizzled Related Protein-2 Expression in Murine Angiosarcoma
por: Tsuruta, James K., et al.
Publicado: (2014)

Triple negative breast cancer: A continuing challenge
por: Gupta, Sudeep
Publicado: (2013)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
por: Wang, Edina, et al.
Publicado: (2018)

Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway
por: Yang, Lihui, et al.
Publicado: (2021)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
por: Zimmerli, Dario, et al.
Publicado: (2022)

Stratifying triple-negative breast cancer: which definition(s) to use?
por: Adamo, Barbara, et al.
Publicado: (2011)

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
por: Katsuta, Eriko, et al.
Publicado: (2019)

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
por: Camarda, Roman, et al.
Publicado: (2016)

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
por: Nakhjavani, Maryam, et al.
Publicado: (2019)

Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells
por: Yin, Shuping, et al.
Publicado: (2017)

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer
por: Nedeljković, Milica, et al.
Publicado: (2019)

High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer
por: Gupta, Nidhi, et al.
Publicado: (2017)

New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription
por: Hu, Ming-Hao, et al.
Publicado: (2019)

PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
por: Hsu, Wen-Jing, et al.
Publicado: (2021)

The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer
por: Jin, Xi-Xin, et al.
Publicado: (2022)

MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
por: Doha, Zinab O., et al.
Publicado: (2023)

Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Shrestha, Sumi, et al.
Publicado: (2018)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Treatment response in triple-negative breast cancer: a role for eEF2 kinase-mediated autophagy?
por: Ho, Cally J., et al.
Publicado: (2020)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

CD44 Targeted Nanomaterials for Treatment of Triple-Negative Breast Cancer
por: Nabil, Ghazal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ufiag8siml96eg41gpboj5r2h